Minnesota's Solventum sells purification business to Thermo Fisher for $4.1 billion
M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to pay down its billions in outstanding debt. Solventum CEO Bryan Hanson said in a news release that the sale,
Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...
Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...
Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Amy Wakeham; SVP of IR; Solventum Corp. Bryan Hanson; CEO & Director; Solventum Corp. Wayde McMillan; CFO; Solventum Corp. Jason Bednar; Analyst; Piper Sandler & Co.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback